264 related articles for article (PubMed ID: 29550382)
21. Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units.
Salvi G; Innocenti I; Autore F; Laurenti L
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015056. PubMed ID: 26543525
[TBL] [Abstract][Full Text] [Related]
22. Chronic lymphocytic leukaemia in pregnancy: a case report and literature review.
Maxwell C; Grady R; Crump M
Obstet Med; 2009 Dec; 2(4):168-9. PubMed ID: 27579065
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Maruyama D; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Kato H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
Haematologica; 2024 Jun; ():. PubMed ID: 38841789
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
Despas F; Chaouki M; de Barros S; Bonneau B; Allal B; Guillermet-Guibert J; Ysebaert L
Leuk Lymphoma; 2024 May; ():1-3. PubMed ID: 38747179
[No Abstract] [Full Text] [Related]
25. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent.
Burgstaller S; Wimmer S; Mayrbaeurl B; Hoebling W; Thaler J
Blood Cancer J; 2011 May; 1(5):e20. PubMed ID: 22829155
[No Abstract] [Full Text] [Related]
26. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.
Nastoupil LJ; Flowers CR
Community Oncol; 2012 Dec; 9(12):S85-S92. PubMed ID: 23316119
[No Abstract] [Full Text] [Related]
27. Lymphocytic Leukæmia under Treatment by Benzol.
Rolleston HD; Boyd EJ
Proc R Soc Med; 1914; 7(Sect Study Dis Child):71-3. PubMed ID: 19978359
[No Abstract] [Full Text] [Related]
28. Case of (?) Lymphocytic Leukæmia.
Thursfield H
Proc R Soc Med; 1926; 19(Sect Study Dis Child):4-5. PubMed ID: 19985299
[No Abstract] [Full Text] [Related]
29. Secondary or Symptomatic Leukæmia.
Ward GR
Proc R Soc Med; 1914; 7(Med Sect):126-58. PubMed ID: 19977944
[No Abstract] [Full Text] [Related]
30. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
31. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
Byrd JC; Smith S; Wagner-Johnston N; Sharman J; Chen AI; Advani R; Augustson B; Marlton P; Renee Commerford S; Okrah K; Liu L; Murray E; Penuel E; Ward AF; Flinn IW
Oncotarget; 2018 Feb; 9(16):13023-13035. PubMed ID: 29560128
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
33. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
34. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Bachy E; Maurer MJ; Habermann TM; Gelas-Dore B; Maucort-Boulch D; Estell JA; Van den Neste E; Bouabdallah R; Gyan E; Feldman AL; Bargay J; Delmer A; Slager SL; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Ansell SM; Lamy T; Dartigues P; Link BK; Seymour JF; Cerhan JR; Salles G
Blood; 2018 Jul; 132(1):49-58. PubMed ID: 29666118
[TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.
Puente XS; Jares P; Campo E
Blood; 2018 May; 131(21):2283-2296. PubMed ID: 29666114
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
[TBL] [Abstract][Full Text] [Related]
37. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
39. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
Vermeulen R; Saberi Hosnijeh F; Bodinier B; Portengen L; Liquet B; Garrido-Manriquez J; Lokhorst H; Bergdahl IA; Kyrtopoulos SA; Johansson AS; Georgiadis P; Melin B; Palli D; Krogh V; Panico S; Sacerdote C; Tumino R; Vineis P; Castagné R; Chadeau-Hyam M; ; Botsivali M; Chatziioannou A; Valavanis I; Kleinjans JCS; de Kok TMCM; Keun HC; Athersuch TJ; Kelly R; Lenner P; Hallmans G; Stephanou EG; Myridakis A; Kogevinas M; Fazzo L; De Santis M; Comba P; Bendinelli B; Kiviranta H; Rantakokko P; Airaksinen R; Ruokojarvi P; Gilthorpe M; Fleming S; Fleming T; Tu YK; Lundh T; Chien KL; Chen WJ; Lee WC; Kate Hsiao C; Kuo PH; Hung H; Liao SF
Int J Cancer; 2018 Sep; 143(6):1335-1347. PubMed ID: 29667176
[TBL] [Abstract][Full Text] [Related]
40. Genetics of diffuse large B-cell lymphoma.
Pasqualucci L; Dalla-Favera R
Blood; 2018 May; 131(21):2307-2319. PubMed ID: 29666115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
